40. Use of a compound according to any one of claims 1 to 36 in the manufacture of a medicament for preventing weight gain or promoting weight loss in an individual in need thereof.

41. Use of a compound according to any one of claims 1 to 36 in the manufacture of a medicament for improving circulating glucose levels, glucose tolerance and/or circulating cholesterol levels, lowering circulating LDL levels, and/or increasing HDL/LDL ratio in an individual in need thereof.

42. Use of a compound according to any one of claims 1 to 37 in the manufacture of a medicament for treating a condition caused or characterised by excess body weight, e.g. the treatment and/or prevention of obesity, morbid obesity, obesity linked inflammation, obesity linked gallbladder disease, obesity induced sleep apnea, pre-diabetes, insulin resistance, glucose intolerance, type 2 diabetes, type I diabetes, hypertension, atherogenic dyslipidimia, atherosclerois, arteriosclerosis, coronary heart disease, peripheral artery disease, stroke or microvascular disease in an individual in need thereof.

~~43. A compound according to claim 39 wherein the compound is administered as part of a combination therapy with an agent for treatment of diabetes, obesity, dyslipidaemia, or hypertension.~~

~~44. A compound according to claim 43 wherein the agent for treatment of diabetes is metformin, a sulfonylurea, a glinide, a DPP-IV inhibitor, a glitazone, insulin or an insulin analogue.~~

~~45. A compound according to claim 43 wherein the agent for treatment of obesity is a glucagon-like peptide receptor 1 agonist, peptide YY or analogue thereof, cannabinoid receptor 1 antagonist, lipase inhibitor, melanocortin receptor 4 agonist, or melanin concentrating hormone receptor 1 antagonist.~~

~~46. A compound according to claim 43 wherein the agent for treatment of hypertension is an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, diuretic, beta-blocker, or calcium channel blocker.~~

~~47. A compound according to claim 43 wherein the agent for treatment of dyslipidaemia is a statin, a fibrate, a niacin and/or a cholesterol absorbtion inhibitor.~~

48. Use according to any one of claims 40 to 42 wherein the compound is administered as part of a combination therapy with an agent for treatment of diabetes, obesity, dyslipidaemia, or hypertension.

49. Use according to claim 48 wherein the agent for treatment of diabetes is metformin, a sulfonylurea, a glinide, a DPP-IV inhibitor, a glitazone, insulin or an insulin analogue.

50. Use according to claim 48 wherein the agent for treatment of obesity is a glucagon-like peptide receptor-1 agonist, peptide YY or analogue thereof, cannabinoid receptor-1 antagonist, lipase inhibitor, melanocortin receptor-4 agonist, or melanin concentrating hormone receptor-1 antagonist.

51. Use according to claim 48 wherein the agent for treatment of hypertension is an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, diuretic, beta-blocker, or calcium channel blocker.

52. Use according to claim 48 wherein the agent for treatment of dyslipidaemia is a statin, a fibrate, a niacin and/or a cholesterol absorbtion inhibitor.